About Enhancer
| Enhancer ID: | E_02_0218 |
| Species: | human |
| Position : | chr7:148804819-148806819   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Sepsis |
| Pubmed ID: | 31518916 |
| Enhancer experiment: | PCR, Western blot, flow cytometry, immunofluorescence staining |
| Enhancer experiment description: | The function of histone methyltransferase enhancer of zeste homolog 2 (EZH2) in sepsis remains unknown. |
About Target gene
| Target gene : | EZH2,STAT3(1110034C02Rik,AW109958,Aprf),SOCS3,STAT1(CANDF7,IMD31A,IMD31B,IMD31C,ISGF-3,STAT91) |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | The function of histone methyltransferase enhancer of zeste homolog 2 (EZH2) in sepsis remains unknown.;Blockage of EZH2 also suppressed the progression of lung injury and alleviated in_x0002_flammation by decreasing the pulmonary cell apoptosis, reducing inflammatory cells infiltration and cytokines release through inhibition of the STAT3 signaling pathway and recovery of PPAR? activation. I;In addition, EZH2 inhibitor blunted macrophage M1 polarization by SOCS3/STAT1 pathway. Overall, these data suggest that EZH2 could be a potential biomarker predicting clinical outcome and a new target for therapeutic interference in sepsis.;In addition, EZH2 inhibitor blunted macrophage M1 polarization by SOCS3/STAT1 pathway. Overall, these data suggest that EZH2 could be a potential biomarker predicting clinical outcome and a new target for therapeutic interference in sepsis. |
About TF
| TF name : | -- |
| TF experiment: | PCR,Western blot,Flow cytometry,?????? |
| TF experiment description: | The function of histone methyltransferase enhancer of zeste homolog 2 (EZH2) in sepsis remains unknown.;Blockage of EZH2 also suppressed the progression of lung injury and alleviated in_x0002_flammation by decreasing the pulmonary cell apoptosis, reducing inflammatory cells infiltration and cytokines release through inhibition of the STAT3 signaling pathway and recovery of PPAR? activation. I;In addition, EZH2 inhibitor blunted macrophage M1 polarization by SOCS3/STAT1 pathway. Overall, these data suggest that EZH2 could be a potential biomarker predicting clinical outcome and a new target for therapeutic interference in sepsis.;In addition, EZH2 inhibitor blunted macrophage M1 polarization by SOCS3/STAT1 pathway. Overall, these data suggest that EZH2 could be a potential biomarker predicting clinical outcome and a new target for therapeutic interference in sepsis. |
About Function
| Enhancer function : | The function of histone methyltransferase enhancer of zeste homolog 2 (EZH2) in sepsis remains unknown. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
The function of histone methyltransferase enhancer of zeste homolog 2 (EZH2) in sepsis remains unknown. |
About SNP
| SNP ID: | -- |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene